SCHEMBL980206

SCHEMBL980206

O=C(O)c1ccccc1-c1ccc2cccc-2o1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.58
KDM4E B2RXH2 3/20 0.58
LMNA P02545 1/20 0.58
ALDH1A1 P00352 5/20 0.53
HPGD P15428 2/20 0.53
KMT2A Q03164 4/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
GAA P10253 1/20 0.50
HNF4A P41235 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NQO2 P16083 3/20 0.45
USP2 O75604 1/20 0.45
TSHR P16473 1/20 0.45
MAPT P10636 1/20 0.45
THRB P10828 1/20 0.45
BLM P54132 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
MYC P01106 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5204502 0.83 KDM4E (0.51) POLBKDM4ELMNAALDH1A1HPGD
SCHEMBL8791374 0.76 KDM4E (0.61) POLBKDM4ELMNAALDH1A1HPGD
SCHEMBL7407371 0.76 HNF4A (0.73) LMNAALDH1A1KMT2ANPC1RAB9A
SCHEMBL32677772 0.74 HNF4A (0.64) ALDH1A1KMT2ANPC1RAB9AHNF4A
SCHEMBL32677769 0.74 HNF4A (0.64) ALDH1A1KMT2ANPC1RAB9AHNF4A
SCHEMBL505412 0.74 HNF4A (0.64) ALDH1A1KMT2ANPC1RAB9AHNF4A
SCHEMBL133057 0.73 HNF4A (0.69) POLBKDM4EALDH1A1HPGDKMT2A
SCHEMBL18759613 0.73 HNF4A (0.63) KDM4EALDH1A1HPGDKMT2ANPC1
Benzene SCHEMBL1403559 0.73 HNF4A (0.69) POLBKDM4EALDH1A1HPGDKMT2A
SCHEMBL30292805 0.73 HNF4A (0.63) KDM4EALDH1A1HPGDKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110021540-A1 Bis-(Sulfonylamino) Derivatives in Therapy 066 ASTRAZENECA AB (SE) 2011-01-27 US disclosed
EP-2217566-A1 BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 AstraZeneca AB (SE) 2010-08-18 EP disclosed
US-20090281138-A1 Bis-(Sulfonylamino) Derivatives in Therapy 066 ASTRAZENECA AB (SE) 2009-11-12 US disclosed
WO-2009064250-A1 BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 ASTRAZENECA AB (SE) 2009-05-22 WO disclosed
WO-2009064251-A1 BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 ASTRAZENECA AB (SE) 2009-05-22 WO disclosed
US-20090131468-A1 Bis-(Sulfonylamino) Derivatives in Therapy 065 ASTRAZENECA AB (SE) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131468-A1 Bis-(Sulfonylamino) Derivatives in Therapy 065 PTGER1, CYP3A5, SULT1E1 POLB 2349/4885KDM4E 1469/4885LMNA 1939/4885
US-20090281138-A1 Bis-(Sulfonylamino) Derivatives in Therapy 066 CYP2D6, PTGER1, CYP2B6 POLB 2046/4885KDM4E 2765/4885LMNA 1378/4885
US-20110021540-A1 Bis-(Sulfonylamino) Derivatives in Therapy 066 CYP2D6, PTGER1, CYP2B6 POLB 2046/4885KDM4E 2765/4885LMNA 1378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.